Download Files:
JNJ-26070109
SKU
HY-111313-Get quote
Category Reference compound
Tags Cholecystokinin Receptor, GPCR/G Protein;Neuronal Signaling, Metabolic Disease
Products Details
Product Description
– JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the research of gastroesophageal reflux disease[1].
Web ID
– HY-111313
Shipping
– Room temperature
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C23H17BrF2N4O3S
References
– [1]Magda F Morton, et al. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011 J
CAS Number
– 844645-08-5
Molecular Weight
– 547.37
SMILES
– O=C(N[C@@H](C1=CC=C(F)C=C1F)C)C2=CC=C(Br)C=C2NS(=O)(C3=C4N=CC=NC4=CC=C3)=O
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– Cholecystokinin Receptor
Isoform
– CCKBR
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.